Monitoring linezolid levels to improve treatment for drug-resistant tuberculosis
Therapeutic drug monitoring for linezolid in the treatment of rifampin-resistant tuberculosis: a pragmatic randomized controlled trial
This study is looking at how keeping track of the right amount of the drug linezolid can help people with rifampin-resistant tuberculosis and HIV feel better and have fewer side effects, by finding the best dose for their treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Albert Einstein College of Medicine NIH-funded |
| Lab location | 1 site (Bronx, United States) |
| Project ID | NIH-11095559 on NIH RePORTER |
What this research studies
This research investigates how monitoring the levels of the drug linezolid can enhance treatment outcomes for patients with rifampin-resistant tuberculosis, particularly those living with HIV. The study aims to identify optimal drug concentrations to minimize side effects while maximizing effectiveness, as high levels of linezolid can lead to serious toxicities. By conducting a pragmatic randomized controlled trial, the researchers will assess the impact of tailored dosing on patient health and treatment success.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults over 21 years old who are diagnosed with rifampin-resistant tuberculosis and may also be living with HIV.
Not a fit: Patients who do not have rifampin-resistant tuberculosis or are not on linezolid treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment protocols that enhance survival rates and reduce side effects for patients with drug-resistant tuberculosis.
How similar studies have performed: Previous research has shown that monitoring drug levels can improve treatment outcomes in other conditions, suggesting a promising approach for this study.
Where this research is happening
Bronx, United States
- Albert Einstein College of Medicine — Bronx, United States (Active)
Researchers
- Principal investigator: Brust, James C M — Albert Einstein College of Medicine
- Study coordinator: Brust, James C M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.